NCT00658437View on ClinicalTrials.gov

CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

May 31, 2010

Conditions
Melanoma
Interventions
DRUG

CY-503

solution for subcutaneous injection, 350 ng twice weekly

Trial Locations (4)

D-10117

Haut Tumor Zentrum Charité, Berlin

D-21603

Dermatologisches Zentrum Elbe-Klinikum Buxtehude, Buxtehude

D-30449

Hautklinik Linden MH Hannover, Hanover

D-24105

Universitäts-Hautklinik Kiel, Kiel

Sponsors
All Listed Sponsors
lead

Cytavis Biopharma GmbH

INDUSTRY